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THE UNIVERSITY OF TENNESSEE
COLLEGE OF VETERINARY MEDICINE

July 16, 1993

ur
Office of the Dean
P. O. Box 1071
Knoxville, TN 37901-1071
(615) 974-7262

The College of Veterinary Medicine, despite reduced state funding, has enjoyed another good year of scholarship.
Our success can be greatly attributed to the flexibility this Center offers in supporting the best and most productive
programs.
While a full search for an assistant/associate dean for research and graduate programs was completed this year, the
College elected to forego filling the position for now. This decision was based on two major criteria: the current
fiscal climate in higher education and information gathered during the search. In the interviewing process, it was
recognized that while modestly funded, we have a firm research foundation and that our College is still recognizing
growth. It was clear from our discussions with all the candidates that we distribute funds fairly and in a clearly
identified manner. Moreover, the excellent scientific recommendations provided by both the external and internal
advisory committees, coupled with the spirit of cooperation and commitment to quality fostered by the Center's
administrators has, even in these fmancially troubled times, maintained excellent progress toward Center goals.
In view of the above fmdings, we feel that additional leadership in research and graduate programs, while desired, is
not yet essential. The College is in the process of hiring a grants and contracts specialists to better oversee the
research funds.

This report documents the success from careful management of COE funding. However, much scholarship is an
indirect result of COE. For example, because of our successive growth, we are able to attract young researchers such
as Dr. Steve Kania who comes to the College with his own funding. His grant entitled "Identification of C3 binding
components that facilitate invasion by Bahesia bigemia" is through the USDA His research intertwines well with Dr.
Leon Potgieter's and our effort in livestock diseases and population medicine.
Other excellent examples of how instrumental COE funds are to the College are:
•

Dr. S. Orosz's project entitled "Evaluation of the pharmacokinetic disposition if Itraconzaole in Blue Fronted
Amazon Parrots" was funded by the Association of Avian Veterinarians. Preliminary data secured with COE
funds allowed her grant to be competitive enough to receive the funding.

•

Dr. Rhea Morgan, a new faculty member, was able to capitalize on her COE seed monies by gaining funds
from Schering-Plough Animal Health to "determine the effectiveness of cyc1osporine ophthalmic ointment in
dog."

As the College advances, COE funds will continue to be counted on to challenge excellence and reward diligence and
dedication as we stay focused on our goals to maintain that cutting edge -- to strive for continual growth. These
funds also provide much needed funding for some exposure to research as a career choice for some of our students.
Sincerely,

~~

fL
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I. PROGRAMMATIC REPORT
LA.

REASSIGNMENT OF CENTER FACULTY
One of the four major research groups, Oncology, has been divided into two
groups.
One of DR. H. SCHULLER'S accomplishments this year, has been to establish
the "Carcinogenesis and Developmental Therapeutics (CDT) Program." This
program, directed by DR. SCHULLER, brings together basic cancer researchers and
clinical oncologists to provide an incentive for interactive disciplinary collaborations
and a forum for guidance and assistance of junior faculty in obtaining outside funds.
Currently, active members of this program include: DRS. K. HAHN and A. Legendre
(clinical veterinary oncology), T. Panella (human clinical oncology), D. McGavin
(pathology), M. MILLER (molecular biology), and H. M. SCHULLER (experimental
oncology). As an initial success of this program, DR. SCHULLER was able to obtain a
contract with a pharmaceutical company for DR. K. HAHN, for a 2-year clinical trial in
dogs with osteosarcomas. It is anticipated that this study will provide convincing
preliminary data useful for the generation of larger grant funds in this area.
Under the direction of DR. T. SCHULTZ, the "In Vitro Toxicology and
Toxicokinetics (IVTT) Group" is comprised of DR. SCHULTZ, DR. D. L. FRAZIER, DR. T.
ROWLES, and Dr. D. Ward. The newly formed program will attempt to carve out a
niche in the vast arena of toxicology by building on the strengths and interests of
existing CVM faculty. DR. T. SCHULTZ brings to the group his long-standing interest
in in vitro toxicity testing, structure-activity, and microscopy. DR. T. ROWLES brings
her interest and expertise in mammalian cell/tissue culture techniques and
neurotoXICIty. DR. D. FRAZIER brings to the group her interest and expertise in
biocheInistry and toxicokinetics. The initial focus of the groups will be on
neurotoxicity. The basic research efforts will be aimed at elucidating the
mechanisms of neurotoxic action. Specifically, the group will collaborate on the
development, validation and use of a novel, complex co-culture system of
endothelial, neuronal and neuroglia cells as an in vitro tool with which to model the
blood-brain barrier (BBB) and its relationship to neurotoxicity. This model will
provide a basis for studies investigating BBB transport and cytotoxicity induced by
other photosensitizing drugs. This program will use as it spring boards the
cooperative agreement with USEP A currently being finalized by DR. T. ROWLES.
These new groups will be structured into the preexisting Growth Factors
Group, Infectious Diseases and Population Medicine Group, and the Inflammation
and Host Defense Group.
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PERSONNEL CHANGES
1.B.1. Personnel Additions
Joms the "Carcinogenesis and Developmental
Therapeutics (CDT) Program." He received both his D.V.M. and Ph.D. from
Purdue University.
DR.

KEVIN

HAHN

1.B.2. Personnel Deletions
DR. MICHAEL BREIDER joined Parke-Davis Pharmaceuticals in Ann
Arbor, Michigan, on January 1, 1993.
DR. DOUG DAWSON leaves the college on June 30, 1993, to accept a
faculty position with Ashland University in Ashland, Ohio.

I.e.

CENTER GOALS
Goal 1: To IMPROVE THE QUALI1Y OF HUMAN LIFE THROUGH BETfER ANIMAL HEALTH.
DR. L. MUNSON made significant progress in understanding the role of
transforming growth factor-Bs in the development of the bovine placenta. She and
her laboratory have determined that TGF-f3s 1-3 promote proliferation of bovine
trophoblastic and endometrial epithelial cells in culture. They also have found that
this atypical action of TGF-f3 may be due to synergism with platelet-derived growth
factors (PDGF). PDGF-af3 is a potent mitogen for their bovine placental and
endometrial cell line and for two primary human endometrial epithelial cell lines
they developed from tissues obtained in collaboration with Drs. Nirmali B.
Upadhyaya and Stuart Van Meter for the UTK Medical Center. She has also
determined through collaboration with DR. J. GODKIN that TGF-f3 is synergistic with
retinoic acid, a substance that also regulate PDGF transcription.
Research performed in DR. J. GODKIN'S laboratory focuses on fetal-maternal
interactions that contribute to the maintenance of pregnancy and growth and
development of the embryo in domestic farm animals. Their efforts have been
concentrated on proteins produced by the blastocyst, extraembryonic placental
membranes and the maternal uterus. The conceptus interferon (INF) tau (7),
formerly called trophoblast protein-l and acknowledged to be the embryonic signal
for early pregnancy maintenance, was demonstrated to diminish uterine cell
prostaglandin (PG) production in vitro. Additionally, interferon 7 inhibited oxytocin
stimulation of uterine cell PG production, illustrating that INF7 maintains early
pregnancy by preventing production of PGF2a, the uterine luteolysin, which causes
the regression of the corpus luteum in cyclic animals. Vitamin A (retinol) is
essential for reproduction and retinoic acid, a natural metabolite of vitamin A, is
believed to be the morphogen that dictates pattern formation in developing
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embryos. They have demonstrated that retinol-binding protein (RBP), the retinol
transport protein, is a product of all extraembryonic placental membranes and the
maternal uterus. Embryonic cell growth, differentiation and cell migration are
believed to be influenced by both humoral factors (such as growth factors and
retinoids) and interaction with the extracellular matrix. It is anticipated that this
project will receive major extramural funding next year. Recently, they have
isolated from placental membrane cultures, a secreted precursor of collagen, an
extracellular matrix protein. This protein has been cloned and sequenced. Currently
studies are examining the role of humoral factors in collagen expression in placental
and uterine cells and the influence of this collagen on cell behavior.
Goal 2: To AUGMENT LIVESTOCK DISEASE RESEARCH CAPABILmES IN THE INSTITUTE OF
AGRICULTURE.

In DR. D. SlAUSON'S studies on the mechanisms of interaction of endotoxin
(LPS) with target cells, his laboratory found that LPS-induced procoagulant activity
in bovine lung macrophages was dependent on the important intracellular signalling
kinase, protein kinase-Co In more recent studies, they have expanded on this initial
finding and have obtained evidence that the proximal signalling pathway may involve a
G-protein-linked receptor as well. This G-protein-linked receptor appears to initiate
signalling through a pathway that may not involve mobilization of Ca2 +.
Additionally, recent research has clearly established the presence and a role for
bovine lipopolysaccharide binding protein (LBP) in the interaction of LPS with
crucial target cells. They are continuing to follow these leads regarding the
transmembrane signalling pathways used by LPS and LPS/LBP complexes in bovine
lung macrophages.
DR. P. BOCHSLER has spent the year purifying and characterizing bovine
lipopolysaccharide-binding protein. He has identified the bovine CD14 receptor
(LBP) and has characterized the response of bovine endothelial cells to endotoxin.
Further, he has characterized the signal transduction in bovine endothelial cells in
response to endotoxin or other stimuli. He is also collaborating on elucidation of
endotoxin-mediated signal transduction pathways in bovine macrophages with DR.
D. SlAUSON.

Goal 3: To IDENTIFY AND CHARACfERIZE ANIMAL DISEASES THAT ARE ANALOGOUS TO

HUMAN

DISEASES.

studied the retroviral vector constructs LCldSN and LHIdSN in
canine marrow cultures and fibroblasts.
Marrow cells from 2
Mucopolysaccharidosis I (MPS I)-affected dogs were infected by vector containing
DR.

R.

SHULL
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supernatant in liquid culture on autologous, pre-established stromal layers. Non
adherent cells from liquid cultures produced iduronidase for ZO days at levels
approximately twice that of endogenous iduronidase in similarly cultured cells from
unaffected dogs. Fibroblasts from an affected dog and a normal control were
similarly transfected with LCldSN. Iduronidase production transfected MPS I
fibroblasts was Z-10 times that of normal dog fibroblasts over a period of 50 days in
culture.
DR. D. DAWSON, in conjunction with DR. T. SCHULTZ, has spent this year
evaluating malformation of Xenopus embryos exposed to selected short-chain
carboxylic acids. Valproic acid is a known human teratogen which causes
malformation of the central nervous system. This acid has been tested in an effort
to determine the structural requirement for the induction of malformation. They
have found that while branching effects metabolism, it is the presence of a 5- or 6
carbon chain that is important for teratogenesis.
DR. T. SCHULTZ is embarking on the third year of a three-year project entitled
"Predictive Toxicities of Selected Oxygen-containing Molecules." The project
centers on examining the toxicity of oxygen-containing aliphatic and aromatic
industrial chemicals specifically alcohols, aldehydes, and esters. Specific aims
concerning toxicity testing and modeling of direct-acting bioreactive aldehydes, have
been completed this past year. This work has shown that testing protocol are directly
correlated with toxicity and the toxicity of aldelydes cannot be extrapolated from one
species to another. Moreover, the test of unsaturated aliphatic alcohols, was also
completed during the year. Results on the relative toxicity ofpropargylic alcohols has
shown these alpha-beta unsaturated alcohols are metabolized to highly toxic ketenes.
Leydig cells in the testis interstitium are the primary source of testosterone in
the adult male mammal. In the steroid synthetic pathway, cholesterol, which is an
obligatory intermediate, needs to be transported into mitochondria to initiate this
process. Despite the vast amount of research conducted on aspects of steroid
hormone biosynthesis in many tissues (such a adrenal, ovary, testis) the mechanism
of cholesterol transport into the inner mitochondrial membrane is poorly
understood. As cholesterol is highly insoluble in water and cannot freely diffuse
within the Leydig cells, existence of a carrier mechanism to perform this function is
speculated. It is known that in liver and adrenal gland sterol carrier protein-Z
(SCPZ), a 14 kDa protein is involved in this carrier mechanism. DR. C. MENDIS
lIANDAGAMA'S previous studies have shown that SCP2 is highly concentrated in
peroxisomes in Leydig cells and that intraperoisomal SCP2 content is regulated by
luteinizing hormone (LH), which stimulates steroid hormone production by Leydig
cells. During the past year, her research efforts have been to carry out preliminary
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studies to investigate the mechanism of cholesterol transport during steroid
hormone biosynthesis in Leydig cells in the testis in response to LH stimulation.
Goal 4: To STUDY ANIMAL MODELS FOR BETrER UNDERSfANDING OF HUMAN DISEASE.
Over the past year, DR. B. ROUSE has succeeded in providing further evidence
in support of the hypothesis that stromal keratitis resulting from Herpes simplex virus
represents an immunopathological reaction mediated by CD4 + T lymphocytes. Their
new data indicate that a single phenotype of CD4 + T cells, the Th 1 phenotype, is
involved in the lesions and that such cells might mediate pathology following their
recognition of a host heat shock protein. Dr. Rouse will also evaluate the ability of
recombinant attenuated Salmonella that express genes of Herpes simplex virus
(HSV) to induce protective immunity against viral challenge in animal model
systems. Special emphasis will be directed at the cytotoxic T lymphocyte response
since it is hypothesized that for solid immunity to HSV this form of immunity must
be included in the immune response. His research will evaluate if a recombinant
attenuated Salmonella vector system hold promise as a means of vaccinating against
HSVinman.
DR. H. SCHULLER'S research programs in the area of lung carcinogenesis and
therapeutics and in the field of transplacental carcinogenesis have continued to
flourish, resulting in an impressive number of publications and presentations.
Among the highlights to Dr. Schuller's work was the discovery that certain
carcinogenic nitrosamines interact with specific signal transduction pathways in selected
cell types thus resulting in continuous cell proliferation leading to cancer. This work
has now generated a new grant with the National Cancer Institute for a period of 5
years. Moreover, Dr. Schuller's research in hamsters has shown, for the first time, that
in utero exposure of fetuses to ethanol and tobacco-specific nitrosamines may cause a
high incidence ofpancreas cancer in the offspring.
Another research project was to adapt the polymerase chain reaction
technique to amplify small quantities of DNA from paraffin-embedded tissues. DRS.
M. MILLER and H. SCHULLER have been successful in obtaining amplified sequences of
the hamster Ki-ras gene. In a recent dose response experiment, a readily detectable
signal could be obtained by Southern blot analysis of the amplified DNA in less than
24 hours of autoradiographic exposure from as little as the equivalent of a 1 micron
piece of tissue from embedded hamster lung samples. This technique should be
readily adoptable for other gene sequences, and the development of this technique
in their laboratories should greatly aid their research efforts. These results have
been used to support NIH grant applications for both investigators.
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During the past year, DR. E. WILKINSON has made considerable progress in
characterizing the phenotype of the cells from Tg737 mice that are responsible for
development of the kidney and liver lesion in this transgenic mouse model of
autosomal recessive polycystic kidney disease. The morphologic studies of the in
vivo lesions including the transmission and scanning electron microscopy have been
completed. Additionally, they have completed the lectin straining for both the liver
and kidneys. Just recently, they have determined that the Tg737 gene codes for a
protein with tetratricopeptide repeats. This is the only gene with this structure yet
identified and characterized in mammalian cells. In lower eucaryootes, a number of
such genes have been identified and are generally associated with regulation of the
cell cycle.
In another collaborative project, DR. B. ROUSE'S laboratory with DR. E.
WILKINSON'S laboratory will continue and expand their studies of the response of scurfy
cells to stimulation. Scurfy is an X-linked lymphoproliferative disease of mice that
results from abnormalities in the development of T cells and depends on the
genotype of the thymus. In these studies, quantitative mRNA expression, capture
ELISAs, and ELISA-SPOT analysis will be done on stimulated scurfy and normal T
cells and purified populations of T cell subsets. These studies should provide
convincing evidence for any imbalance in Thl and TH2 CD4 + T cells in scurfy.
Goal 5: To UNDERSrAND THE PATHOGENESIS AND CHARACfERIZE THE CAUSATIVE AGENTS OF
COMMON DISEASES IMPORTANT TO TENNESSEE.
Coronaviruses cause the most economically important disease in chickens,
avian infectious bronchitis, and are a cause of one of the most economically
important disease syndromes in pigs and calves, neonatal scours. In pigs alone, the
estimated annual cost in the U. S. due to coronavirus enteritis is 200 million dollars.
DR. .D. BRIAN'S laboratory, which is entirely devoted to the study of coronaviruses,
investigates coronaviruses that infect many animal species, including humans, and
cause disease ranging from severe acute respiratory and gastroenteric disease to
chronic disease of the central nervous system. Recent evidence suggests that human
coronavirus is causally related to multiple sclerosis. Dr. Brian's laboratory has recently
cloned a subgenomic replicon of the bovine coronavirus that is proving useful for
establishing the mechanisms of coronavirus RNA replication and persistence. The
replicon may prove useful as an exciting new recombinant vaccine vehicle for
stimulating mucosal immunity and for delivering medically therapeutic molecules.
Over the past year, a major research focus in DR. S. OLIVER'S laboratory has
been on Streptococcus uberis, an important mastitis pathogen that is very difficult to
control.
Results of these studies have shown that both encapsulated and
unencapsulated strains of 5.. uberis adhere to bovine mammary epithelial cells and to
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extra cellular matrix proteins such as laminin, fibronectin and collagen. Preliminary
studies suggest that adherent bacteria become internalized or penetrate a bovine
mammary epithelial cell line. If internalization occurs in vivo, this could allow S.
uberis to evade host defenses, and gain access to stromal tissue. Studies are in
progress to determine if epithelial cell internalization is a potential virulence factor
in the pathogenesis of S. uberis mastitis. They showed that encapsulated strains of
S. uberis were more resistant to phagocytosis by mammary gland macrophages than
unencapsulated strains. Thus, the capsule which surrounds about 50% of S. uberis
isolates may be a virulence factor by inhibiting phagocytosis. They also evaluated
the use of new epidemiological markers to studying S. uberis mastitis in dairy cows.
Results showed that polymerase chain reaction-based DNA fingerprinting and
bacteriocin-like inhibitory substance (BLIS) fingerprinting as epidemiological markers
allowed tracing of an infection by the same clonal type in a cow over time. New
intramammary infections by different clonal types were also identified. Lastly, a
polymerase chain reaction-based DNA fingerprinting assay was developed as a method
for identification of Streptococcus and Enterococcus species isolated from bovine milk.
Several studies were initiated/completed in DR. J. OLIVER'S laboratory during
the past year. The first project entitled "Lysergic acid amide (lysergamide)
vasoconstrictor activity in the lateral saphenous vein and dorsal metatarsal artery of
cattle" encompassed lysergamide induced contraction in these blood vessels which
has considerable biological implications to the fescue toxicosis syndrome. USDA
researchers identified this alkaloid in 1991 as being one of the major alkaloids present
in endophyte-positive fescue grass. The alkaloid was determined to have affinity for
the serotonergic-2 (5-HT2) receptor, which is present in many organ systems,
including the brain, kidneys, and gastrointestinal tract in particular. Thus, the
alkaloid may ultimately be proven to have important biomedical uses in addition to
contributing to the toxic fescue syndrome. Work has also been completed in
describing the use of the Alzet™ osmotic pump system for dosing animals with
purified alkaloids found in toxic tall fescue. The technique will continue to be used
in studies designed to determine the chronic effects of toxic fescue alkaloids on
tissues. Further, HPLC methodology has been developed and published to
determine the content of lysergamide in cattle serum. DR. 1. OLIVER'S group was the
first to report detecting this important new alkaloid of toxic fescue in the sera of cattle
grazing endophyte-positive fescue pastures. Finally, efforts continue to secure funds
from pharmaceutical firms to develop an anti-fescue toxicosis vaccine, for which Dr.
Oliver has applied for a patent.
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Goal 6: To IMPROVE THE CAPABILmES OF THE COLLEGE OF VETERINARY MEDICINE, THE
COLLEGE OF AGRICULTURE, AND THE AGRICULTURAL EXPERIMENT STATION TO DEAL
WITH THESE DISEASES.

Work continues on the molecular biology and immune response to bovine
viral diarrhea virus. DR. L. POTGIETER'S laboratory has as their goal with BVDV
research, the development of improved diagnostics and immunoprophylaxis.
Investigation focuses on the structural proteins of this virus. These proteins are
responsible for induction of the protective immune response. The three major
structural protein-encoding genes have been cloned, analyzed, and expressed. Using
these expression products, their goal is to develop a sensitive and specific serological
test that is very economical. Further, these proteins may be subcloned into live virus
vectors for use in recombinant live vaccines. Antibodies induced by these proteins
in animals were found to have neutralizing capabilities. This pathogen is associated
with respiratory and reproductive disease leading to considerable financial loss.
Improvement in these two areas of BVDV control, diagnosis and immunoprophylaxis,
will have significant impact on the cattle industry.
Additionally, work is ongoing to evaluate the ovine respiratory syncytial virus
at the molecular level. The surface protein responsible for viral attachment and
induction of protective immunity to this virus, the G glycoprotein, has been cloned
and sequenced, and the nucleotide sequence has been extensively analyzed. The
gene encoding the nonstructural proteins IA, IB, and IC of ORSV has also been
cloned, sequenced, and analyzed. This is the only ruminant RSV lA -C genes to be
sequenced to date. Cloning and sequencing of the G glycoprotein of ovine RSV adds
to the information they have from the bovine RSV. This knowledge will be useful
for the development of sensitive and specific diagnostic assays, as well as for the
development of an effective vaccine. Further, the analogy to the human RSV may
prove to be very useful for development of a suitable animal model for this significant
human pathogen. This work is of interest to NIH, and we anticipate significant
extramural funding next year. The sequencing of the 1C gene will also be important
for guiding vaccine and diagnostic assay development.
Goal 7: To IMPROVE FACILITIES TO ENABLE TIlE COLLEGE OF VETERINARY MEDICINE TO SI'UDY
MORE EFFECTIVE INFECTIOUS AND TOXIC DISEASES AFFECTING ANIMALS.

The COE research efforts are housed in the Clyde M. York Veterinary
Medical Teaching Hospital which contains clinical and teaching facilities as well as
modern research laboratories. Other collaborative research space is located in
McCord Hall (Animal Science), Walters Life Science Building (Microbiology), and
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at the University of Tennessee Medical Center and Memorial Research Hospital
(Medical Biology).
The center enjoys excellent, but not expansive, research and graduate
education facilities. The past several of years have been difficult ones from a fiscal
standpoint, and little funds have been available for the expansion of facilities. We
regard talented people as more important than facilities, and in the past few years,
we have had to focus our attention on not losing any important human resources.
Funds have recently been made available for the planning phase of a new
Biotechnology Building on the Institute of Agriculture Campus. If USDA and State
of Tennessee matching funds can be secured, such a building would provide at least
some additional research space for COE researchers and graduate students.
Goal 8: To DISSEMINATE THROUGH THE EXTENSION SERVICE THE PRAcrICAL INFORMATION
REQUIRED TO REDUCE THE INCIDENT OF LIVESTOCK DISEASES.
UTCVM has been featured in several publications over the course of the
year. UT Agriculture, published by the Institute of Agriculture and encompassing a
large statewide audience, featured an article on DR. T. SCHULTZ pertaining to
toxicological issues as they relate to birth defects. Veterinary Medical Topics,
published semi-annually by the Extension Service, routinely features articles
exploring livestock diseases. Channel 10 featured the genetic mouse model that is
part of DR. E. WILKINSON'S research. This same feature was later picked up and
shown nationally on CNBC. Regular features appear as well in the two UT alumni
publications, Context and the Torchbearer.
Goal 9: To DEVELOP NEW STRATEGIES FOR THE PREVENTION OF DISEASE.
During the past year, COE has supported DR. K. HAHN'S two Cytogenetics
Laboratory pilot investigations in genetic toxicology.
Project 1 entitled
"Quantification of in vitro induced sublethal DNA damage by photodynamic
therapy," determined if chloroaluminum-sulfonated phthalocyanine (AISPc)
photodynamic therapy (PDT) caused sublethal DNA damage in EMT-6 mouse
sarcoma cells treated in vitro. The second project titled "Micronuclei assay: A
predictive indicator for tumor response to treatment" determined if anti-neoplastic
drugs such as cyclophosphamide, doxorubicin HCI, and cis-diammine-dichloro
platinurnII induced sublethal DNA damage in normal circulating canine peripheral
blood lymphocytes cultured in vitro and if the degree of damage was of predictive
value for in vivo treatment response in tumor-bearing dogs. The endpoint of study
for both projects was evaluating the formation of cellular micronuclei. Micronuclei are
fragments of DNA packaged independently during cellular division and are
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quantitatively significant as an indicator of sublethal DNA damage. With this prelinary
data, Dr. Hahn plans to submit a first investigator's grant to NIH.
DR. T. ROWLES has begun developing protocols for in vitro testing and kinetics
of neurotoxicants. Cytotoxicity assays in endothelial, glial, and neuronal cells were
established. Toxicant testing is planned for next year. Additionally, an in vitro
model of the blood-brain barrier will be developed by co-culturing these cell types.
Goal 10: To IMPROVE FACILITIES AND EXPERTISE IN ORDER TO PROVIDE IMPROVED RESEARCH
TRAINING.
SPECIAL MATERIALS AND EQUIPMEI\'T
Equipment monies this year were spent on assisting with the establishment of
laboratories of three new Center members--DRS. K. HAHN, C. MENDIS-HANDAGAMA, and
T. ROWLES. This mainly encompassed upgrade tissue culture and molecular biology
capabilities. As well, several multiuser pieces of equipment were purchased,
including three centrifuges, a gas chromotograph, and a tumor analysis system.
GRADUATE STUDENTS. POST DOCTORAL RESEARCHERS. AND RESIDENTS
Dr. David Dean, sponsored by DR. D. SLAUSON, was the first student in the
college to receive an individual NIH research training grant. He is studying the
"Signalling pathways in LPS-stimulated lung macrophages."
Dr. Donna Bouley became the second student in the college to receive an
individual NIH research training grant. Under the direction of her advisor, DR. B.
ROUSE, Dr. Bouley will study "Herpetic stromal keratitis pathogenesis: An animal
model."
These NRSA Fellowship Awards are very competitive at a national level, so
it is very gratifying that these proposals have been selected for funding. COE
monies are used to support the research of our NRSA fellows.
Our training program is small, but high in quality. An institutional training
grant has been submitted by DR. D. SLAUSON, Department of Pathobiology. If
funded, it will support five graduate students/residents selected from the
Comparative and Experimental Medicine Graduate Program. These students will
train in the area of "Cellular Pathobiology of Environmental Disease." The program
will be a collaborative effort between the Department of Pathobiology and the
Biology Division at Oak Ridge National Laboratory. The program will seek to
produce individuals who, by virtue of their training, will be uniquely equipped to address
such important environmental research priorities as the molecular and genetic basis for
disease, genetic and membrane events that may control differentiation and
development, the role of receptor-mediated pathobiology including transmembrane
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signal transduction, molecular mechanisms of chemical carcinogenesis, and the
molecular and genetic basis for immunologic susceptibility and predisposition. The
graduates of this program should then be able to contribute to an enhanced
understanding of the environmentally-caused disorders of man and other animals
both in terms of the morphologic expressions of disease and in terms of its
molecular and cellular pathogenesis.
Several young research associates and residents have benefited directly from
the use of COE funding to provide for preliminary data via venture grants. A few
examples include Dr. Huda AI-Ansari, a post doctoral research associate, with DR.
L. POTGIETER who received funding from USDA for their project entitled
"Significance of strain variation within the ruminant respiratory syncytial viruses."
This funding will enable them to determine the seroprevalence of the prototype
ORSV in cattle, to determine variability among BRSV isolates using RNase A
mismatch analysis, and to establish the number of RSV subgroups infecting cattle.
These goals could provide important data that would help determine which RSV strains
should be incorporated into a multivalent vaccine to effectively control the disease in
cattle.
Dr. Wendy Davies-Dean has received a grant from the American Animal
Hospital Association (AAHA) for $6,100 for her study entitled "Evaluation of
intraosseous administration of total parenteral nutrition in cats." Nutritional
support of injured or ill dogs and cats is recognized as a vital component of case
management. Her goal is to provide an option for practitioners in cases where
parenteral nutritional support is necessary but delivery by traditional routes has failed or
is impossible. Hopefully by making parenteral nutrition more accessible, this
potentially lifesaving therapy will be used more routinely.
MINORITY RECRUITMENT

To compliment the Minority High School Apprentice Program sponsored by
the National Institutes of Health (now in its 12th year), a new veterinary internship
for African-American High School Students in Tennessee has been developed with
funding provided by a grant from the Tennessee Higher Education Commission.
While the students participating in the NIH sponsored program spend 8 weeks at
the college, the veterinary internship program participants sponsored by THEC, will
be working with a veterinarian in their home towns for eight weeks during which
one week they will be introduced to the UTCVM and UT campus.
Through our minority internship/residency program, UTCVM has been
successful in recruiting 5 minorities for the upcoming fiscal year.
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COLLABORATIVE RESEARCH PROJECTS

To further determine if absence of PDGF-Q receptors interferes with
placental growth, DR. L. MUNSON is now collaborating with the University of
Washington-Seattle to evaluate a spontaneous PDGF-Q receptor-deficient mouse
model, the Patch mouse. To evaluate placental development in the Patch mouse,
they have developed riboprobes and initiated in situ hybridization techniques in
their laboratory. These new molecular techniques will be used to identify
homozygous PDGF-QR mutant embryos so that the development of their placenta
can be evaluated.
In collaboration with Dr. Ellis Avner of the University of Washington,
Seattle, DR. E. WILKINSON has begun to characterize the kidney cells involved in the
production of the lesions in the Tg737 mice. Their preliminary data suggests that
the cells are principal cells and that the lesion develops as a result of a failure of
maturation of the principal cells and the differentiation into the specialized intercalated
cells. Similarly, the liver lesion appears to arise from a failure of differentiation of
the liver stem cells into mature biliary epithelium.
In other studies, they have cloned and sequenced the human homolog of the
mouse Tg737 gene and established the molecular structure of the intron-exon
boundaries. In collaboration with Dr. Steve Reeders of Howard Hughes Medical
Institute, Yale University, they are examining the structure of the Tg737 gene in over
100 human families with autosomal recessive polycystic kidney disease. Further, Dr.
Wilkinson has also completed collaborative studies with Dr. Greg Dressler of the
National Institutes of Health (NIH) on the nature of the congenital nephrotic
syndrome in PAX-2 transgenic mice.
As well, Dr. Wilkinson's laboratory has established cultures of liver and kidney
cells from Tg737 mice. Several lines of liver cells have been developed and from
mice with different genetic backgrounds.
A Cooperative Research and
Development Award has been established through the Oak Ridge National
Laboratory and Proctor & Gamble to further characterize the putative liver stem
cells.
Collaborative work was initiated between DR. J. OLIVER and researchers at
the University of Arkansas to characterize the activity of a purified ergovaline
preparation developed by them using Dr. Oliver's isolated bovine blood vessel model.
Further, collaborative work has also been initiated between Dr. Oliver with other
UTCVM researchers and Clemson University, to characterize in utero biochemical
changes in placental fluids in mares on endophyte-infested and endophyte-free tall
fescue pastures. Two graduate students, one resident and five faculty members
between the two institutions are involved in the project.
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Goal 11: To DEVEWP INNOVATIVE APPROACHES TO THE TREATMENT OF HUMAN DISEASE.
One aspect of DR. B. ROUSE'S work involves designing delivery vehicles that
optimize induction of cytotoxic T lymphocytes with viral proteins and peptides. This
program, which proceeds collaboration with Dr. Leaf Huang, University of
Pittsburgh, uses liposomes as carriers of autogens and adjuvants. This approach to
vaccinate may prove valuable to prevent certain human virus infections.
The effects of sex- and strain-related differences in megakaryocytopoiesis
and platelet production in C3H and BALB/C mice were studied during the year by
DR. T. McDoNALD.
The studies were carried out on castrated male and
ovariectomized female C3H and BALB/C mice, along with suitable intact controls.
The results support their previous work, showing that intact male BALB/C mice
had higher platelet counts and %35 S incorporation into platelets than did intact
female BALB/C mice. Further, both intact BALB/C and C3H male mice had
higher platelet counts than their castrated counterparts. Castration caused
increased numbers and decreased sizes of megakaryocytes in both strains of mice.
Although a difference in megakaryocyte ploidy was not detected between intact
male and intact female C3H mice, BALB/C female mice had lower ploidy
megakaryocytes than did BALB/C male mice. Castrated BALB/C mice had lower
ploidy megakaryocytes than did intact BALB/C male mice. They found a shift to a
lower ploidy class with the removal of gonads in male mice; therefore, they believe
that this finding is consistent with the hypothesis that male sex hormones cause an
In order to understand
increase in polyploidy and size of megakaryocytes.
thrombocytopoiesis during pregnancy, megakaryocytes and platelets were examined
during gestation and the early postpartum period, using the rat as a model. Mean
platelet volume and platelet volume distributions were not significantly altered in
late gestation of rats. Also, they showed that platelet survival in pregnant rats was
not significantly different from that of non-pregnant females.
In contrast,
megakaryocyte concentration was significantly increased during late gestation and
early postpartum. Their data indicate that thrombocytopoiesis is substantially
increased during late pregnancy, and that this increase is accompanied through an
increase in megakaryocyte DNA content and size, as well as, megakaryocyte number.
The data also revealed that pregnancy-associated hormonal changes which produce an
increase in megakaryocyte DNA content and size differ from those which cause an
increase in megakaryocyte number.
During the past year, COE provided support for a post-doctoral fellow to
work with DRS. D. FRAZIER and DR. M. BREIDER. The project entitled "Enhancement
of photodynamic tumor therapy with angiogenic cytokines" was supported by the
Thompson Cancer Survival Center. This project examined the effect of cytokines on
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cytOXIClty induced by photsensitizing drugs in tumor cells and endothelial cells.
Preliminary drug transport studies were conducted. The proposal to the Beckman
Laser Institute will examine transport of these photosensitizing agents across the blood
brian barrier and cytotoxicity to neuroblastoma cells, brian capillary endothelial cells
and astrocytes. COE has also provided support for two doctoral students. The two
projects (1) use of photodynamic therapy for autologous bone marrow
transplantation and (2) synergistic activity of cisplatin and radiation, will be
completed this year.
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II. BENCHMARKS
Table 1. CENTER OF EXCELLENCE IN LIVESTOCK DISEASES AND HUMAN HEALTH
BENCHMARKS OF FACULTY ACCOMPLISHMENTS
FACULTY MEMBERS ASSOCIATED
WITH THE CENTER OF EXCELLENCE

Year 5
(Final Year of
Initial Commitment)
1988-89
Target Actual Avg

Year 6
(Year 01 as
Accomplished Center)
1989-90
Actual
Avg

Year 7
(Year 02 as
Accomplished Center)
1990-91
Avg
Actual

YearS
(Year 03 as
Accomplished Center)
1991-92
Actual
Avg

Year 9
(Year 04 as
Accomplished Center)
1992-93
Actual
Avg

A. Numbers of
74

1. Articles

(3.22)

68

(2 .62)

97

(3.73)

83

(4.37)

78

(3.90)

b::I

~

;:::s

("')

2. Books or book chapters published

7

(0.30)

17

(0.65)

14

(0.54)

6

(0.32)

7

(0.35)

21

(0.91)

37

(1.42)

42

(1.62)

24

(1 .26)

17

(0.85)

;:s

~
~

3. Published proceedings
2.82

102

(4.43)

122

(4.69)

153

(5.89)

113

(5.95)

102

(5.10)

1. Regional Meetings

0.50

36

(1 .56)

19

(0.73)

28

(1 .08)

13

(0.68)

15

(0.75)

2. National Meetings

1.25

55

(2.39)

28

(1 .08)

44

(1 .69)

36

(1 .89)

47

(2.35)

0.30

33

(1 .43)

66

(2 .54)

48

(1 .85)

47

(2.47)

53

(2.65)

Total Publications:

~

B. *Number of invited participations at:

C. Abstracts
Number of faculty included in Center
Number of Visitors

11

23

26

26

19

20

10

17

17

12

12

I-l
~
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TABLE 2.
RESEARCH PROJECTS FUNDED EXTERNALLY
REPORT PERIOD 1992-93
TOTAL AMOUNT
AWARDED

ESTIMATED
EXPENDITURES
7-1-92/6-30-93

PROJECT DIRECTOR

SOURCE

BOCHSLER, P. N.
Bovine Lipoplysaccharide Binding
Protein and Mechanisms of
Macrophage Activation

USDA
9/1/91-8/31/93
(Extension to 8/31 /94)

BOCHSLER, P. N.
Molecular Basis of
Endothelial Cell Sensitivity to
Lipopolysaccharide

USDA
9/15/92-9/30/94

95,000

37,601

BOCHSLER, P. N.
The Bovine CD 14 Receptor:
A Link in Endotoxin-mediated
Macrophage Activation

USDA
9/15/92-9/30/94

150,000

59,375

BRIAN, D. A.
Corona virus Structure and
Replication

NIH
9/1/89-8/31/94

552,187

140,716

BRIAN, D. A.
Mechanism(s) of Corona virus
RNA Replication and Packaging

USDA
9/15/92-9/30/95

200,000

52,782

DAWSON, D. A.
SCHULTZ, T. W., Co-investigator
Mixture Teratogenesis: Relation
to Mechanisms and QSARs

NIEHS/NIH
4/1/91-3/31/93

138,043

51,768

HAHN, K.
SCHULLER, H. M., Co-investigator
Contract--B859-035 Treatment
of Dogs with Osteosarcoma

BYK Gulden
Pharmaceuticals
1/1/93-12/31/95

63,890

21,120

McDoNALD, T. P.
Contract--Development of Assays
for Thrombopoietin

Genentech
3/1/88-2/28/93
(Extension to 2/28/95)

175,832

29,304

Performance of Assays for
Thrombopoietin

3/1/88-7/31/93
(Extension to 2/28/95)

112,700

18,780

McDoNALD, T. P.
Characterization of
Thrombopoietin

AmGen
10/1/92-12/31/95

73,671

17,001

McDONALD, T. P.
Thrombopoietin: Immuno
assay & Characterization

NIH
12/1/88-11/30/93

548,681

109,740

140,000

42,000
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TOTAL AMOUNT
AWARDED

ESTIMATED
EXPENDITURES
7-1-92/6-30-93

PROJECT DIRECTOR

SOURCE

McDONALD, T. P.
Purchase of: Matrix 96 Direct
Beta Counter

NHLBI Small
Instrumentation Program
9/1/92-8/31/93

17,225

17,225

MUNSON, L.
The Pathological Effects of
Melengestrol Acetate in Captive
Wild Felids

AAZPA
Conservation Center
10/1/92-9/30/93

37,807

28,359

OLIVER, S. P.
Mastitis Research

Alcide Corporation
12/90-12/94

57,752

14,438

OLIVER, S. P.
Mastitis Research

Monsanto Agri Co
11/90-12/92

25,576

12,788

OLIVER, S. P.
Factors Influencing Bovine
Mononuclear Cell Function during
the Nonlactating Period

USDA-SEA
9/ 90-9/ 92

98,388

12,300

OLIVER, S. P.
Mastitis Research

H. B. Fuller Co.
4/ 91 -12/94

31 ,778

8,664

Effectiveness of
chlorhexidine as a premilking
teat disinfectant for the
prevention of bovine mastitis

H. B. Fuller Co.
1992-1993

24,052

12,026

Chlorhexidine Milk Residues
Associated with Premilking
and Postmilking Teat
Disinfection

H. B. Fuller Co.
1992-1993

3,732

3,732

OLIVER, S. P.
Mastitis Research

Upjohn Company
10/91 -12/94

6,293

1,992

Immunization of dairy cows
against Streptococcus uberis:
Efficacy of an Experimental
Vaccine during the Nonlactating
Period

Upjohn Company
1991-1993

54,225

27,112

OLIVER, S. P.
Selenium and Vitamin E in
Disease Resistance

BASF
1992-1993

17,000

10,000

OLIVER, S. P.
Use of Genetic Markers as
Indicators of Mastitis
Resistance and Milk Production
in Jersey Cattle

American Jersey
Cattle Club
1993

6,000

3,000
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PROJECT DIRECTOR

SOURCE

TOTAL AMOUNT
AWARDED

ESTIMATED
EXPENDITURES

7-1-92/6-30-93
POTGIETER, L.
Development of Technology for
use in the Discovery and
Production of a Commercial BVD
Vaccine and Diagnostic
POTGIETER, L.
Cloning and Sequencing of BRSV
G Glycoprotein and Detection
of Strain Divergence
ROUSE, B. T.
Immunity Mechanisms in
Herpesvirus Infections

Upjohn Company

75,000

25,000

149,974

49,991

1,130,370

234,132

718,935

38,907

774,745

152,586

828,289

162,807

124,746

25,000

9,484

789

100,000

48,504

491,219

93,137

464,975

176,642

382,925

52,497

2/1/90-12/31/92

USDA Special
Grant

8/1/90-7/31/93

NIH

5/1/89-4/30/94

National Eye
Institute (NIH)

ROUSE, B. T.
Keratitis Treatment with Drugcontaining Immunoliposomes

9/30/87-9/29/92

Mechanisms in Herpetic
Stromal Keratitis

National Eye
Institute (NIH)

9/30/92-9/29/97
ROUSE, B. T.
Liposome Microencapsulation
of Vaccine Antigens

NIAID

6/1/90-5/31/95

ROUSE, B. T.
Herpes Zosterification

Smithkline Biologicals

ROWLEST. K.
Characterization Isolated
Rodent Microvesse/sj
Astrocytes Co-cultures

Environmental Protection
Agency (EPA)

SCHULLER, H. M.
Mechanisms of Neuroendocrine
Lung Carcinogenesis by
Nitrosamines

Shannon Award
Institute (NIH)

SCHULLER, H. M.
Transplacental
Carcinogenicity of NNK

NIH

SCHULLER, H. M.
Characterization of Induced
Neuroendocrine Lung Cancer
SCHULLER, H. M.
Contract--Testing of Anticarcinogenic Effects of
Niguldipine

12/15/89-12/31/94

4/7/93-4/6/95

9/1/91-8/31/93

9/1/89-11/30/92
(Extension to 11/30/93)
National Cancer
Institute (NIH)

2/7/92-1/31/95
Byk Gulden
Pharmaceuticals

3/1/88-12/31/94

Benchmarks

PROJECT DIRECTOR

SCHULTZ,

T.

W.

Chaos in Microbial Systems
SHULL,

R.

Molecular Study of MPS I:
Gene Therapy in a Canine Model

SOURCE

NSF
12/1/89-11/30/92
NIH
8/1/92-7/31/96
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TOTAL AMOUNT
AWARDED

ESTIMATED
EXPENDITURES
7-1-92/6-30-93

111 ,615

15,500

1,001,653

114,944

120,000

39,000

97,500

26,540

SLAUSON, D. O.
Leukocyte Function and Host
Defense in Developing Calves

USDA Competitive
8/15/90-9/30/93
(Extension to 9/30/93)

SLAUSON,

D., Advisor for
D.Dean
Signalling Pathways in LPSStimulated Lung Macrophages

NIH Training Grant
11/30/ 91 -11/30/94

WILKINSON, J. E. &
GODKIN, J., Co-investigator

USDA Special
8/1/89-6/30/92
(Extension to 6/30/93)

149,653

35,488

NIH
9/30 / 92-9/29/95

406,639

121 ,608

NIH
9/ 30 / 92-5/31/95

579,594

143.464

Transforming Growth Factors in
Early Pregnancy in the Cow
WILKINSON,

J. E.

Molecular Genetics of PKD in
the Transgenic TG737 Mouse
WILKINSON,

J. E.

Immunobiology of the Scurfy
Mouse

Total

$2,288,359
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III. PLANS FOR NEXT YEAR
CARCINOGENESIS AND DEVELOPMENTAL THERAPEUTICS GROUP
DR. H. SCHULLER will continue to pursue research goals and devote considerable
efforts to the integration of other faculty into the interdisciplinary research programs under
the umbrella of the "Carcinogenesis and Developmental Therapeutics Program. Dr.
Schuller has served on four NIH site visit teams for the review of Cancer Center grants and
program project grants, and she was an ad hoc member of two NIH study sections. She has
agreed to become a regular member of the NIH chemical pathology study section in
January 1994. Dr. Schuller has also been appointed as associate editor of the international
journal Carcinogenesis.
Fetal tissues are more sensitive to the effects of chemical and physical carcinogens
than are adult tissues. This suggests that the embryos and fetuses of pregnant women are
at a greater risk of developing cancer from environmental exposures than is the adult
population. It is thus important to gain further understanding of the mechanism(s) that
help modulate the fetal organism's response to environmental toxicants, and to determine
how the genetic background of the individual fetus and its mother can modulate its
response to envrionmental carcinogens. DR. M. MILLER'S goal for the coming year is to
determine the molecular mechanisms governing the pathogenesis of lung tumors in mice
differing in their susceptibility to polycylic hydrocarbon-mediated tumor formation. The
data will show how the genetic make-up of the individual and the modulating influences of
maternal phenotype can influence susceptibility to cancer as a result of early in utero
exposure to environmental chemicals.
DR. K. HAHN'S long term goal for the Cytogenetics Laboratory is to determine the in
vitro and/or in vivo efficacy of novel cancer treatment strategies using proven methods in
genetic toxicology. With recent support from Bristol Laboratories and the National Cancer
Institute of donated drugs, he will seek to determine quantitatively if SR-2508
(etanidazole), an oxygen-mimetic nitroimidazole, potentiates sublethal DNA damage and
cytotoxicity in EMT-6 tumor cells and/or normal peripheral blood lymphocytes when
concurrently exposed to subtherapeutic doses of either radiation or chemotherapy in vitro.
GROWTH FACTORS GROUP
DR. R. SHULL will continue to investigate methods of either stem cell enrichment or
elimination of differentiated cells from populations to be subjected to gene transfer. Even
with relatively high titer vectors, working with unenriched marrow mononuclear cells
requires very large volumes to be effective. Monoclonal antibodies to c-kit, the target for
stem cell factor have been obtained, and they will test these by FACS in the coming year.
Another antibody (DH59B) reacts with an epitope on differentiated granulocytes and
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For DR. T. ROWLES, next year will involve further development of protocols for the in
vitro assessment of neurotoxicity. These protocols include transport studies, transepithelial
electrical resistance and biochemical assays. Such protocols will be used to assess the
integrity of an in vitro model of the blood brain barrier. A valid model of the blood brain
barrier will allow drug and toxicant testing with a reduction in the number of animals used and
an increase in the numbers of chemicals tested. Additionally, this model will provide a way
to study mechanisms of neurotoxicity.
DR. D. FRAZIER is working with DRS. T. ROWLES and T. SCHULTZ to develop an in vitro
model of the blood-brain barrier for evaluation of transport and cytotoxicity of
environmental toxicants and cancer chemotherapeutics. Preliminary studies of Dr. Frazier
and others suggested that cytokines are important mediators of transport of cytotoxic drug!!
across peripheral capillary endothelial cells and into tumor cells. Angiogenic cytokines
may be even more important as mediators of transport across brain capillary endothelial
cells (blood-brain barrier).
INFECTIOUS DISEASES AND POPULAnON MEDICINE GROUP
DR. D. BRIAN'S research is a systematic analysis of the molecular structure,
replicational strategy, and medical significance of coronaviruses, one family of RNA viruses
that cause primarily gastroenteric and respiratory diseases in animals and humans. Their
major effort focuses on two gastroenteric coronaviruses, the porcine, transmissible,
gastroenteritis, coronavirus (TGEV) and the bovine enteric coronavirus (BCV). Both are
significant veterinary pathogens and each serves as a model for one of two major antigenic
subgroups of mammalian centeric coronaviruses. They also conduct some studies on the
mouse hepatitis coronavirus and human coronaviruses.
Additional structural and nonstructural protein-encoding genes of ORSV have been
cloned in DR. L. POTGIETER'S laboratory. In the next year, these ORSV recombinant clones
will be sequenced and analyzed, as has been done for the G and 1C genes. They also plan
to subclone the ORSV genes into the baculovirus expression system for production and
analysis of ORSV proteins. Eventually, they hope to evaluate the immune response to, and
correlates of protection for ruminant RSV. Furthermore, since it is not known if ovine
RSV strain is circulating in cattle, his laboratory plans to assess the presence of antibodies
to their ovine RSV G glycoprotein serum samples from cattle in different geographical
locations using a sensitive immunoassay such as ELISA. Such information is important to
determine strain variability among cattle and to identify the strain necessary for inclusion
in any multivalent vaccine. They also plan to continue investigation of the protective
nature of the structural proteins of BVDV individually and in combination with one
another, as well as continue efforts to develop economical and accurate diagnostic assays.
DR. J. OLIVER will participate in endophyte-free and endophyte-positive tall fescue
pasture studies. Studies will include collection of both forage from pastures and serum
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from cattle throughout the grazing season to determine alkaloid content by HPLC and GC
methods. These profiles will be correlated with other physiological response factors,
including animal growth, hair quality scores, serum prolactin, serum endothelin and serum
cortisol levels.
DR. S. OLIVER will be working on a new project entitled "DNA probes for typing and
sub typing bacterial pathogens isolated from dairy cattle." Application of DNA probes for
identification and sUbtyping of pathogenic bacteria could allow diagnostic laboratories to
examine a wider variety of organisms, enable identification of bacterial pathogens that
cannot be cultured easily in vitro, allow rapid screening and subtyping of a large number of
organisms which would be very useful during an outbreak of an animal disease, enhance
development of strategies for monitoring disease control programs and reduce costs of
handling, processing, identification and subtyping of bacterial pathogens. The objective for
the first year of this study is to develop a model system for identification of pathogenic
bacteria using specific oligonucleotide primers targeted at 16 S rRNA sequences.
INFLAMMATION AND HOST DEFENSE GROUP
During the next academic year DR. B. ROUSE'S efforts will be directed at finding
explanations for the preferential accumulation of CD4 + T cells in ocular tissues identifying
possible target antigens which they recognize and evaluating the role of nitric oxide radicals
as responsible for tissue damage.
DR. P. BOCHSLER will expect to explore new research possibilities as they arise by
incorporating new techniques, and by pursuing collaborative studies when bovine LBP is
isolated and purified in sufficient quantity. Should opportunity arise, to continue PMN
related research, he would like to continue this as time and personnel allow. A specific
goal is to have at least three research manuscripts published in refereed journals.
The specific goals for DR. D. SLAUSON for the coming year are to continue to dissect
the signalling pathways used by LPS and LPS /LBP complexes for pro coagulant induction
and TNF-a release in bovine lung macrophages with special attention directed at the
potential role of a G-protein linked receptor in the proximal pathway and a C-kinase as a
terminal activator. The data his laboratory has been able to obtain to date support their
contention that the pathways used by LPS are at least partially G-protein-linked and PKC
dependent. A second objective will be to determine the role of Ca2 + in these signalling
pathways.
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REPORT F
SCHEDULE 1
TENNESSEE HIGHER EDUCATION COMMISSION
CENTERS OF EXCELLENCE
1992-93 BUDGET AND PROPOSED 1993-94 BUDGET
1992-93 Actual EX[1enditures

Matching
Revenue
,
New State Appropriation
Carryover from Previous Appropriation
New Matching Funds
Carryover from Previous Matching
Total
Expenditures
Salaries
a. Faculty
b. Other Professional
c. Clerical/Supporting
d. Assistantships
e. Studentlfotal Salaries
Fringe Benefits
Total Personnel
Travel
Software
Books and Journals
Other Supplies
Equipment

~~t~~~'l,rCfees
c 0 ars IpS

Am~ro[1riations

506,500

1993-94 Pro[1osed Budge!

Total

Matching

506,500

A[1[1ro[1riations

Total

506,000
15,068

521,068

506,000
15,068*
253,000
7,579
781,647

81,988
103,963
35,600
17,550
17,6Z5
255,776
53,816
309,591
3,335

122,920
155,867
53,373
26,312
25,000
383,472
80,683
464,1,55
5,000

95,219
100,050
10,005
2,868

143,i92
150,000
15,000
4,300

317,492

253,250

506,500

759,750

253,000
7,579
260,579

39,250
54,020
18,240
5,070
Z;566
124,146
23,045
147,191
416

78,620
108,203
36,539
10.,155
' 15,149
248,666
46,158
294,824
835

117,870
162,223
54,779
15,225
22,115
372,812
69,203
442,015
1,.251

40,932
51,904
17,773
8,762
8,325
127,696
26,867
154,563
1,665

33,874
58,277
4,525
1,389

67,851
116,075
9,063
2,783

101,725
174,262
13,588
4,172

98,481

195,607

294,998

106,016

211,477

245,6Z1

491 ,432

737,013

260,579

521,068

253,250

253,250

· 47,974
49,950
4,995
1,433

Consultants
Renovation
Other (Specify)
Total Non-personnel

GRAND TOTAL

*There was $6790 obligated in equipment that did not get paid in 92-93.

78~,647

--------------------------~/~J~

NAME:
TITLE:
APPOINTMENT:

Kevin A. Hahn
Assistant Professor
Dept. of Environmental Practice

EDUCATIONAL BACKGROUND:
Degree
PhD
DVM
BS

Year
1992
1987
1983

University
Purdue
Purdue
Purdue

Major
Cytogenetics/Oncology
Veterinary Medicine
Animal Sciences

CAREER HISTORY:
Year(s)
1991 - present
1987 - 1992
1988 - 1991
1987 - 1988

Title
Assistant Professor of Oncology
Cytogenetics Research Fellow
Clinical Oncology Resident
Clinical Oncology Intern

Employer
Univ. of Tennessee
Purdue University
Purdue University
Purdue University

PROFESSIONAL SOCIETIES:
American Veterinary Medical Association, Veterinary Cancer Society, Veterinary Cooperative
Oncology Group, American Association for Cancer Research, Association of Cytogenetic
Technologists, International Society for the Study of Comparative Oncology, American Cancer
Society, Knox County Unit.
SCIENTIFIC PUBLICATIONS
- Abstracts. Proceedings, & Non-peer reviewed, (total - 41). 1992 - July 1. 1993:
Hahn KA, Morrison WB, Chan TC. The concentration of doxorubicin and its associated
metabolites in canine urine following a single administered dose. Tenth Annual Forum, American
College of Veterinary Internal Medicine, San Diego, CA. May 28-31, 1992.
Hahn KA, Vonderhaar MA, Teclaw RF. An epidemiological evaluation of 1202 dogs with
testicular neoplasia. Tenth Annual Forum, American College of Veterinary Internal Medicine, San
Diego, CA. May 28-31, 1992.
Hahn KA, Richardson RC. The diagnostic and prognostic importance of cytogenetic aberrations
identified in spontaneously occurring canine malignant lymphoma. Twelfth Annual Conference,
Veterinary Cancer Society, Monterey, CA. October 18-21, 1992.
Bravo L, Hahn KA, Legendre AM, Daniel GB, Frazier DL, Rohrbach BW. Evaluation of pre
and post-cisplatin renal function in 23 tumor-bearing dogs. Twelfth Annual Conference, Veterinary
Cancer Society, Monterey, CA. October 18- 21, 1992.
Arrington KA, Frazier DL, Tabeling GS, Hahn KA, Legendre AM. The comparison of
pharmacokinetics, hematologic parameters, and clinical signs of doxorubicin administration in small
and large dogs. Twelfth Annual Conference, Veterinary Cancer Society, Monterey, CA. October
18-21, 1992.
Hahn KA, Richardson RC. The cytogenetic evaluation of 61 dogs with non-Hodgkin's lymphoma
(NHL). Eighty-fourth Annual Meeting, American Association for Cancer Research, Orlando, FL.
May 19-22, 1993.
Hahn KA. Prognostic Tumor Markers. Eleventh Annual Forum, American College of Veterinary
Internal Medicine, Washingtion, DC. May 20-23, 1993.

- Referreed Journals (total - 17). 1992 - July 1. 1993:

Hahn KA, Richardson RC, MA Cline, Teclaw RF, Carlton WW, DeNicola DB, and PL Bonney.
Is Maintenance Chemotherapy Appropriate for the Management of Canine Malignant Lymphoma? J
Vet Int Med 1992;6:3-10.
Hahn KA, Widmer WR. What is Your Diagnosis. J Amer Vet Med Assoc 1992;200:221-222.
Hahn KA, Knapp DW, Richardson RC, Matlock C. The Clinical Response of Nasal
Adenocarcinoma to Cisplatin Chemotherapy in 11 Dogs. J Amer Vet Med Assoc 1992;200:355-357.
Hahn KA, Richardson RC, Knapp DW. Canine Malignant Mammary Neoplasia: Biological
Behavior, Diagnosis, and Treatment Alternatives. J Amer Anim Hosp Assoc 1992;28:251-256.
Peter AT, Scheidt AB, Campbell JW, Hahn KA. Male pseudohermaphroditism of the testicular
feminization type in a heifer. Canadian Vet. Journal 1993; in press.
Hahn KA, Chan TCK, Morrison WB, Hahn EA. High performance liquid chromatographic
analysis of doxorubicin and its metabolites in canine urine. J Amer Anim Hosp Assoc, 1993; in
press.
Hahn KA, Richardson RC, Hahn EA. Identification and quantification of serum a1pha
fetoprotein in 50 dogs with spontaneously occurring tumors. Res Vet Sci, 1993; submitted.
Hahn KA, Richardson RC, Hahn EA, Chrisman CL. The diagnostic and prognostic importance
of cytogenetic aberrations identified in spontaneously occurring canine malignant lymphoma. Vet
Path 1993; submitted.
Bravo L, Hahn KA, Legendre AM, Daniel GB, Frazier DL, Rohrbach BW. Evaluation of renal
function in 23 tumor bearing dogs treated with cisplatin. J Vet Int Med 1993; submitted.
Hahn KA, DeNicola DB, Richardson RC, Hahn EA. Canine oral malignant melanoma: The
prognostic utility of an alternative staging scheme and a review of 41 cases. J Small Anim Pract
1993; submitted.
RESEARCH - (Accepted proposals - 22; support - $281 .133). 1992 - July 1. 1993:
Hahn KA, Frazier DL, Breider MA, Panjehpour M. Quantification of Photodynamic and
Hyperthermic Induced In vivo Sub-lethal DNA damage. Submitted to Center of Excellence, College
of Veterinary Medicine, University of Tennessee. Accepted July 1, 1992, $15,000.
Hahn KA. Micronuclei Assay: A Predictive Indicator for Tumor Response to Treatment.
Submitted to University of Tennessee College of Veterinary Medicine, Venture Grant Program.
Accepted July 1, 1992, $3,762.
Bravo L, Legendre AM, Hahn KA, Lothrop CD. Serum cytokine concentrations in normal dogs
and in dogs with lymphoma before and after chemotherapy. Venture Grant Program, University of
Tennessee College of Veterinary Medicine. Accepted July 1, 1992, $2,000.
Hahn KA, Schuller HS, Legendre AM. B859-035 (Dexniguldipine) treatment of dogs with
spontaneously occurring osteogenic sarcoma. Byk Gulden Pharmaceuticals, Hamburg, Germany.
Accepted January 1, 1993, $63,890.
Hahn KA. Promoting the responsible handling of anticancer drugs by veterinary personnel. The
Minkel Grant Program, University of Tennessee. Accepted January 28, 1993, $2,300.
Hahn KA. Use of SR-2508 in in vitro an in vivo clinical studies. National Cancer Institute.
Accepted March 22, 1993. Drug support (Approximate value, $4,000).
Hahn KA. Efficacy of SR-2508 as a radiosensitizer at low and high radiation doses. University
of Tennesssee College of Veterinary Medicine Center of Excellence. Accepted July 1, 1993.
$17 ,300.
Hahn KA. Evaluation of cisp1atin toxicity modulation by etanidazole. Venture Grant Program,
University of Tennessee College of Veterinary Medicine. Accepted July 1, 1993. $1,500.
Frazier DL, Hahn KA. Cisplatin pharmacokinetics and clinical response in the dog. Supported,
in part, by Bristol Laboratories (Approximate support, $35,000).
Frazier DL, Hahn KA. Adriamycin pharmacokinetics and clinical response in the cat.
Supported, in part, by Adria Laboratories (Approximate support, $35,000).
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